Mammalian cell surface antigens; related reagents

Abstract

Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.

1 - 41 . (canceled) 
   
   
       42 . A monoclonal antibody that specifically binds a polypeptide having 100% sequence identity with at least 12 contiguous residues of SEQ ID NO: 2. 
   
   
       43 . The monoclonal antibody of  claim 42  wherein said polypeptide consists of a polypeptide having at least 90% sequence identity to residues 205 to 316 of SEQ ID NO: 2. 
   
   
       44 . The monoclonal antibody of  claim 42  wherein said polypeptide is soluble. 
   
   
       45 . The antibody of  claim 42 , wherein the antibody is recombinantly produced. 
   
   
       46 . The antibody of  claim 45 , wherein the antibody is a chimeric, humanized, or human antibody. 
   
   
       47 . A monoclonal antibody that specifically binds a polypeptide having 100% sequence identity with at least 16 contiguous residues of SEQ ID NO: 2. 
   
   
       48 . The monoclonal antibody of  claim 47  wherein said polypeptide consists of a polypeptide having at least 90% sequence identity to residues 205 to 316 of SEQ ID NO: 2. 
   
   
       49 . The monoclonal antibody of  claim 47  wherein said polypeptide is soluble. 
   
   
       50 . The antibody of  claim 47 , wherein the antibody is recombinantly produced. 
   
   
       51 . The antibody of  claim 50 , wherein the antibody is a chimeric, humanized, or human antibody. 
   
   
       52 . A monoclonal antibody that specifically binds a polypeptide having 100% sequence identity with at least 20 contiguous residues of SEQ ID NO: 2. 
   
   
       53 . The monoclonal antibody of  claim 52  wherein said polypeptide consists of a polypeptide having at least 90% sequence identity to residues 205 to 316 of SEQ ID NO: 2. 
   
   
       54 . The monoclonal antibody of  claim 52  wherein said polypeptide is soluble. 
   
   
       55 . The antibody of  claim 52 , wherein the antibody is recombinantly produced. 
   
   
       56 . The antibody of  claim 55 , wherein the antibody is a chimeric, humanized, or human antibody. 
   
   
       57 . An antibody that specifically binds a polypeptide having at least about 90% sequence identity to residues 205 to 316 of SEQ ID NO: 2, wherein the polypeptide comprises at least about 8 contiguous residues of SEQ ID NO: 2 within residues 205 to 316 of SEQ ID NO: 2. 
   
   
       58 . An antibody that specifically binds a polypeptide having at least about 90% sequence identity to residues 205 to 316 of SEQ ID NO: 2, wherein the polypeptide comprises at least about 12 contiguous residues of SEQ ID NO: 2 within residues 205 to 316 of SEQ ID NO: 2. 
   
   
       59 . An antibody that specifically binds a polypeptide having at least about 90% sequence identity to residues 205 to 316 of SEQ ID NO: 2, wherein the polypeptide comprises at least about 16 contiguous residues of SEQ ID NO: 2 within residues 205 to 316 of SEQ ID NO:2. 
   
   
       60 . An antibody that specifically binds a polypeptide having at least about 90% sequence identity to residues 205 to 316 of SEQ ID NO: 2, wherein the polypeptide comprises at least about 20 contiguous residues of SEQ ID NO: 2 within residues 205 to 316 of SEQ ID NO: 2. 
   
   
       61 . The antibody of  claim 42 , wherein the antibody binds a 499E9 polypeptide, wherein binding of the antibody sterically blocks binding of the 499E9 polypeptide to a binding partner of the 499E9 polypeptide. 
   
   
       62 . The antibody of  claim 61 , wherein the binding partner is a ligand or receptor of the polypeptide. 
   
   
       63 . The antibody of  claim 57 , wherein the antibody sterically blocks binding of a polypeptide having 90% sequence identity to residues 205 to 316 of SEQ ID NO: 2 to a binding partner of the 499E9 polypeptide. 
   
   
       64 . The antibody of  claim 63 , wherein the binding partner is a ligand or receptor of the polypeptide. 
   
   
       65 . A method of antagonizing the development of hematopoietic cells comprising administering an antagonist of a 499E9 polypeptide, wherein the antagonist comprises the antibody of  claim 42 . 
   
   
       66 . A method of antagonizing the development of hematopoietic cells comprising administering an antagonist of a 499E9 polypeptide, wherein the antagonist comprises the antibody of  claim 57 . 
   
   
       67 . A method of treating a T-cell mediated condition comprising administering a therapeutically effective amount of an antibody of  claim 42 . 
   
   
       68 . A method of treating a T-cell mediated condition comprising administering a therapeutically effective amount of an antibody of  claim 57 . 
   
   
       69 . A method of modulating T-cell mediated interactions with cells containing a receptor therefor, comprising administering a therapeutically effective amount of an antibody of  claim 42 , wherein the T-cell mediated interactions involve T-cells containing a 499E9 polypeptide. 
   
   
       70 . A method of modulating T-cell mediated interactions with cells containing a receptor therefor, comprising administering a therapeutically effective amount of an antibody of  claim 57 , wherein the T-cell mediated interactions involve T-cells containing a 499E9 polypeptide. 
   
   
       71 . A method of treating a condition characterized by abnormal hematopoietic cell development comprising administering a therapeutically effective amount of an antibody of  claim 42 . 
   
   
       72 . A method of treating a condition characterized by abnormal hematopoietic cell development comprising administering a therapeutically effective amount of an antibody of  claim 57 .